Dachaigh › Aillse a' bhroilleach › Missouri › Kansas City
Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Kansas City, MO
Tha 34 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann agus timcheall air Kansas City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Vanguard Study: Testing a New Way to Screen for Cancer
A’ fastadhFàilte do shaor-thoilich fhallain
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A’ fastadhÌre 3
- University of Kansas Cancer Center, Westwood · 5 mìle air falbh
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A’ fastadhÌre 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A’ fastadhÌre 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A’ fastadhÌre 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A’ fastadhÌre 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
A’ fastadhÌre 3
- The University of Kansas Cancer Center, Westwood · 5 mìle air falbh
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A’ fastadhÌre 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
A’ fastadhÌre 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A’ fastadhÌre 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A’ fastadhÌre 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A’ fastadhÌre 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A’ fastadhÌre 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
A’ fastadhÌre 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A’ fastadhÌre 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
A’ fastadhÌre 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- agus 1 a bharrachd
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- agus 2 a bharrachd
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
A’ fastadhÌre 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A’ fastadhÌre 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- University of Kansas Medical Center (KUMC), Westwood · 5 mìle air falbh
HER2-positive Breast Cancer Registry
A’ fastadhSgrùdadh amharc
- The University of Kansas Cancer Center, Westwood · 5 mìle air falbh
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- agus 1 a bharrachd
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
A’ fastadhÌre 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A’ fastadhÌre 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · 5 mìle air falbh
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
A’ fastadhÌre 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · 5 mìle air falbh
- KUCC - Olathe, Westwood · 5 mìle air falbh
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A’ fastadhÌre 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A’ fastadhÌre 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mìle air falbh
- agus 1 a bharrachd
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
A’ fastadhÌre 1/2
- The University of Kansas Cancer Center, Westwood · 5 mìle air falbh
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A’ fastadhSgrùdadh amharc
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- agus 1 a bharrachd
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
A’ fastadhSgrùdadh amharc
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · 5 mìle air falbh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
A’ fastadhÌre 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mìle air falbh
- agus 1 a bharrachd
Sgrùdaidhean Aillse a' bhroilleach ann am bailtean eile
- New York City, NY136 sgrùdaidhean
- Houston, TX126 sgrùdaidhean
- Boston, MA112 sgrùdaidhean
- Nashville, TN81 sgrùdaidhean
- Los Angeles, CA73 sgrùdaidhean
- Edison, NJ68 sgrùdaidhean
- St. Louis, MO64 sgrùdaidhean
- Queens, NY64 sgrùdaidhean
- Durham, NC64 sgrùdaidhean
- Chicago, IL59 sgrùdaidhean
- Philadelphia, PA56 sgrùdaidhean
- Dallas, TX55 sgrùdaidhean
Sgrùdaidhean eile ann an Kansas City
- Aillse Sgamhain Neo-chealla-beag31 sgrùdaidhean
- Fàilligeadh a' Chridhe25 sgrùdaidhean
- Aillse (gach seòrsa)21 sgrùdaidhean
- Ailseachadh nan Sgamhan19 sgrùdaidhean
- Aillse colorectal16 sgrùdaidhean
- Ailse metastatach15 sgrùdaidhean
- Leukemia myeloid geur15 sgrùdaidhean
- Aillse Prostata14 sgrùdaidhean
- Cancer Ovarian11 sgrùdadh
- Obesity11 sgrùdadh
- Diabaitis Seòrsa 211 sgrùdadh
- Galarachd Cardiovasculach11 sgrùdadh
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.